Issue Archive

Edited by Associate Editor Laurie Sehn, this How I Treat series features 5 state-of-the-art advisory pieces on how experts tackle recurring medical problems that may arise in the context of successful treatment for patients with lymphoid malignancies. Using case-based scenarios, the authors lay out recommendations for diagnosis, prevention, and treatment, providing clinicians with practical advice on how to optimize care for these patients, including through prevention.

In a Plenary Paper, Mittelman and colleagues assess the relative clinical efficacy of mRNA vaccination on COVID-19 disease incidence and outcomes in patients with hematologic malignancies compared with healthy matched controls. This population-based study from Israel links prior observations of poor serologic responses to vaccination to higher risk for breakthrough infection, hospitalization, and death in patients with blood cancer, especially those on active antineoplastic therapy. In an accompanying Letter to Blood, Pagano et al provide supportive data using a multination survey approach to capture outcomes for COVID-19 in vaccinated patients with hematologic neoplasms. They also emphasize the higher risk among patients with lymphoid malignancies. Together, these findings argue for both continued deployment of booster programs and ongoing public health guidance for this vulnerable group.

Hematopoietic stem cell transplantation from relatives sharing only 1 haplotype is revolutionizing curative approaches to patients with poor-prognosis acute leukemias. This Plenary Paper by Fuchs et al addresses the clinically relevant issue of the role of donor-recipient HLA matching on the unshared haplotype. They demonstrate that the specifics of single-locus mismatches matter with respect to risk of relapse and survival, with immediate implications for optimizing donor selection. The authors offer a Web-based tool to enable transplant physicians to make use of these findings.

Edited by Associate Editor Laurie Sehn, this How I Treat series features 5 state-of-the-art advisory pieces on how experts tackle recurring medical problems that may arise in the context of successful treatment for patients with lymphoid malignancies. Using case-based scenarios, the authors lay out recommendations for diagnosis, prevention, and treatment, providing clinicians with practical advice on how to optimize care for these patients, including through prevention.

Edited by Associate Editor Laurie Sehn, this How I Treat series features 5 state-of-the-art advisory pieces on how experts tackle recurring medical problems that may arise in the context of successful treatment for patients with lymphoid malignancies. Using case-based scenarios, the authors lay out recommendations for diagnosis, prevention, and treatment, providing clinicians with practical advice on how to optimize care for these patients, including through prevention.

Edited by Associate Editor Laurie Sehn, this How I Treat series features 5 state-of-the-art advisory pieces on how experts tackle recurring medical problems that may arise in the context of successful treatment for patients with lymphoid malignancies. Using case-based scenarios, the authors lay out recommendations for diagnosis, prevention, and treatment, providing clinicians with practical advice on how to optimize care for these patients, including through prevention.

Edited by Associate Editor Laurie Sehn, this How I Treat series features 5 state-of-the-art advisory pieces on how experts tackle recurring medical problems that may arise in the context of successful treatment for patients with lymphoid malignancies. Using case-based scenarios, the authors lay out recommendations for diagnosis, prevention, and treatment, providing clinicians with practical advice on how to optimize care for these patients, including through prevention.

Edited by Associate Editor Laurie Sehn, this How I Treat series features 5 state-of-the-art advisory pieces on how experts tackle recurring medical problems that may arise in the context of successful treatment for patients with lymphoid malignancies. Using case-based scenarios, the authors lay out recommendations for diagnosis, prevention, and treatment, providing clinicians with practical advice on how to optimize care for these patients, including through prevention.

The specifics of how bone marrow niche cells regulate hematopoietic stem cell (HSC) function and population dynamics require further elucidation. Yu and colleagues provide a mechanistic understanding of how the secreted molecule angiopoietin-like protein 2 (ANGPTL2), specifically that derived from endothelial cells, is important for maintenance of HSC repopulation capacity, quiescence, and localization in the vascular niche.

Using whole-genome CRISPR library screening, Ishio et al identified the genes critical for proliferation and survival of adult T-cell leukemia/lymphoma (ATL) cells. Their data are consistent with the notion that the causative virus, human T-lymphotropic virus 1, targets regulatory T cells for its survival by modulating specific gene networks and that these networks remain indispensable for ATL cells. This research spotlights and preclinically tests potential therapeutic targets for this intractable disease, particularly cyclin-dependent kinase 6 (CDK6) and the mTORC1 pathway.

Kolijn and colleagues provide insights into the earliest phases of emergence of a B-cell clone destined to become monocloncal B-cell lymphocytosis (MBL) and later chronic lymphocytic leukemia (CLL). Through analyses of the B-cell receptor immunoglobulin heavy-chain gene repertoire in serial blood samples collected in a longitudinal study of healthy recruits, they identify clonal skewing up to 16 years before diagnosis of CLL, including in patients later diagnosed with unfavorable-risk disease. While this study extends our insight into the disease's natural history, it has no prognostic impact or implications for clinical assessment.

ADAMTS13 is a plasma metalloprotease that targets the vascular adhesive glycoprotein von Willebrand factor and is a natural antithrombotic. South et al describe their research to develop ADAMTS13-based products as thrombolytics. They describe the design, construction, and in vitro testing of constitutively active ADAMTS13 mutants, as well as in vivo testing of a lead molecule in models of murine ischemic stroke, with data suggesting a beneficial effect.

In a Plenary Paper, Mittelman and colleagues assess the relative clinical efficacy of mRNA vaccination on COVID-19 disease incidence and outcomes in patients with hematologic malignancies compared with healthy matched controls. This population-based study from Israel links prior observations of poor serologic responses to vaccination to higher risk for breakthrough infection, hospitalization, and death in patients with blood cancer, especially those on active antineoplastic therapy. In an accompanying Letter to Blood, Pagano et al provide supportive data using a multination survey approach to capture outcomes for COVID-19 in vaccinated patients with hematologic neoplasms. They also emphasize the higher risk among patients with lymphoid malignancies. Together, these findings argue for both continued deployment of booster programs and ongoing public health guidance for this vulnerable group.